India's Glenmark Life Sciences posts higher Q1 revenue on API boost
BENGALURU, July 25 (Reuters) -Indian drugmaker Glenmark Life Sciences GLEM.NS posted a higher first-quarter revenue on Thursday, driven by strong demand in its mainstay active pharmaceuticals ingredients business.
The Mumbai-based company said revenue from operations rose 2% to 5.89 billion rupees ($70.3 million). Its API business, which accounts for almost all of its revenue, climbed 6.2% from last year.
APIs are key biologically active elements in a drug and are responsible for producing desired health effects.
However, the company's profit fell 18% to 1.11 billion rupees, as it was impacted by inventory-related expenses worth 414.3 million rupees.
For further earnings highlights, click nFWN3JH1W7
KEY CONTEXT
Glenmark Life, like other Indian API makers, has been benefiting from increasing demand in its key European and U.S. markets and is expected to continue benefiting as global drugmakers seek to reduce their reliance on China.
Glenmark Life has over 130 APIs in its portfolio across key therapy areas such as cardiovascular, oncology and anti-infectives.
PEER COMPARISON
Estimates (next 12 months) | Analysts' sentiment | ||||||||
RIC | PE | EV/EBITDA | Revenue growth (%) | Profit growth (%) | Mean rating* | # of analysts | Stock to price target** | Div yield (%) | |
Glenmark Life Sciences | GLEM.NS | 18.26 | 12.05 | 13.30 | 15.44 | Buy | 4 | 0.94 | 3.88 |
Granules India | GRAN.NS | 20.66 | 11.68 | 12.76 | 36.42 | Strong Buy | 4 | 1.12 | 0.29 |
Laurus Labs | LAUL.NS | 48.16 | 20.09 | 16.13 | 103.08 | Hold | 11 | 1.12 | 0.18 |
Sun Pharmaceutical Industries | SUN.NS | 33.41 | 24.63 | 10.25 | 10.95 | Buy | 30 | 1.01 | 0.85 |
* Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT
APRIL TO JUNE STOCK PERFORMANCE
-- All data from LSEG
-- $1 = 83.7804 Indian rupees
($1 = 83.7580 Indian rupees)
APRIL TO JUNE STOCK PERFORMANCE https://tmsnrt.rs/3zWRWe7
Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza and Tasim Zahid
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
